Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model.

Faure K, Fujimoto J, Shimabukuro DW, Ajayi T, Shime N, Moriyama K, Spack EG, Wiener-Kronish JP, Sawa T.

J Immune Based Ther Vaccines. 2003 Aug 13;1(1):2.

2.

Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Sawa T, Ito E, Nguyen VH, Haight M.

Hum Vaccin Immunother. 2014;10(10):2843-52. doi: 10.4161/21645515.2014.971641.

PMID:
25483637
3.

PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.

Wang Q, Li H, Zhou J, Zhong M, Zhu D, Feng N, Liu F, Bai C, Song Y.

Respir Physiol Neurobiol. 2014 Mar 1;193:21-8. doi: 10.1016/j.resp.2014.01.001. Epub 2014 Jan 10.

PMID:
24418353
4.

Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP.

J Immunol. 2001 Nov 15;167(10):5880-6.

5.

PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.

Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, Lynch SV.

Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1837-45. doi: 10.1007/s10096-011-1509-2. Epub 2011 Dec 21.

PMID:
22187351
6.

The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T.

Hum Vaccin Immunother. 2016 Nov;12(11):2833-2846. Epub 2016 Jul 25.

PMID:
27454613
7.

Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.

Moriyama K, Wiener-Kronish JP, Sawa T.

Microbiol Immunol. 2009 Nov;53(11):587-94. doi: 10.1111/j.1348-0421.2009.00165.x.

8.

Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.

Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, Kohno S.

Eur Respir J. 2007 May;29(5):965-8. Epub 2007 Feb 14.

9.

A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.

Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91. doi: 10.1128/AAC.02643-14. Epub 2014 May 19.

10.

IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia.

Katoh H, Yasumoto H, Shimizu M, Hamaoka S, Kinoshita M, Akiyama K, Sawa T.

Crit Care Med. 2016 Jan;44(1):e12-24. doi: 10.1097/CCM.0000000000001271.

PMID:
26317571
11.

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T.

J Infect Dis. 2002 Jul 1;186(1):64-73. Epub 2002 Jun 14.

PMID:
12089663
12.

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.

Ernst EJ, Hashimoto S, Guglielmo J, Sawa T, Pittet JF, Kropp H, Jackson JJ, Wiener-Kronish JP.

Antimicrob Agents Chemother. 1999 Oct;43(10):2389-94.

13.

Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.

Shimizu M, Katoh H, Hamaoka S, Kinoshita M, Akiyama K, Naito Y, Sawa T.

J Infect Chemother. 2016 Apr;22(4):240-7. doi: 10.1016/j.jiac.2016.01.006. Epub 2016 Feb 8.

PMID:
26867796
14.

Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy.

Lynch SV, Flanagan JL, Sawa T, Fang A, Baek MS, Rubio-Mills A, Ajayi T, Yanagihara K, Hirakata Y, Kohno S, Misset B, Nguyen JC, Wiener-Kronish JP.

Microb Pathog. 2010 Jun;48(6):197-204. doi: 10.1016/j.micpath.2010.02.008. Epub 2010 Mar 6.

15.
16.

Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.

Pankhaniya RR, Tamura M, Allmond LR, Moriyama K, Ajayi T, Wiener-Kronish JP, Sawa T.

Crit Care Med. 2004 Nov;32(11):2293-9.

PMID:
15640644
17.

In the absence of effector proteins, the Pseudomonas aeruginosa type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responses.

Audia JP, Lindsey AS, Housley NA, Ochoa CR, Zhou C, Toba M, Oka M, Annamdevula NS, Fitzgerald MS, Frank DW, Alvarez DF.

PLoS One. 2013 Nov 27;8(11):e81792. doi: 10.1371/journal.pone.0081792. eCollection 2013.

18.

Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.

Yasumoto H, Katoh H, Kinoshita M, Shimizu M, Hamaoka S, Akiyama K, Naito Y, Sawa T.

Microbiol Immunol. 2016 Feb;60(2):114-20. doi: 10.1111/1348-0421.12353.

PMID:
26696420
19.

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.

Fran├žois B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J.

Crit Care Med. 2012 Aug;40(8):2320-6. doi: 10.1097/CCM.0b013e31825334f6.

PMID:
22622405
20.

[Effects of Sophora flavescens on rat model of chronic Pseudomonas aeruginosa biofilm pneumonia].

Guo X, Guo R, Song Z.

Zhongguo Zhong Yao Za Zhi. 2010 Feb;35(3):352-5. Chinese.

PMID:
20423004

Supplemental Content

Support Center